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Pulse pressure (PP) is an independent risk factor for
cardiovascular (CV) disease and death but few studies have
investigated the effect of antihypertensive treatments in
relation to PP levels before treatment. The Avoiding Cardio-
vascular Events Through Combination Therapy in Patients
Living With Systolic Hypertension (ACCOMPLISH) trial
showed that the combination of benazepril+amlodipine
(B+A) is superior to benazepril+hydrochlorothiazide (B+H)
in reducing CV events. We aimed to investigate whether the
treatment effects in the ACCOMPLISH trial were dependent
on baseline PP. High-risk hypertensive patients (n=11,499)
were randomized to double-blinded treatment with single-
pill combinations of either B+A or B+H and followed for 36
months. Patients were divided into tertiles according to their
baseline PP and events (CV mortality/myocardial infarction
or stroke) were compared. Hazard ratios (HRs) for the
treatment effect (B+A over B+H) were calculated in a Cox
regression model with age, coronary artery disease, and
diabetes mellitus as covariates and were compared across
the tertiles. The event rate was increased in the high tertile of
PP compared with the low tertile (7.2% vs 4.4% P<.01). In
the high and medium PP tertiles, HRs were 0.75 (95%
confidence interval [CI], 0.60–0.95; P=.018) and 0.74 (CI,
0.56–0.98, P=.034), respectively, in favor of B+A. There was
no significant difference between the treatments in the low
tertile and no significant differences in treatment effect when
comparing the HRs between tertiles of PP. B+A has superior
CV protection over B+H in high-risk hypertensive patients
independent of baseline PP although the absolute treatment
effect is enhanced in the higher tertiles of PP where event
rates are higher. J Clin Hypertens (Greenwich). 2015;17:141–
146. ª 2014 Wiley Periodicals, Inc.
Hypertension has been identified as the most important
global risk factor for premature death. It causes 45% of
deaths caused by heart disease and 51% of deaths
caused by stroke.1 Rapsomaniki and colleagues recently
highlighted the importance of blood pressure (BP) for
various manifestations of cardiovascular (CV) disease in
1.25 million patients. Diastolic and systolic pressure
associations were not concordant, and pulse pressure
(PP), rather than systolic BP (SBP), was associated with
some CV diseases.2 The Avoiding Cardiovascular
Events Through Combination Therapy in Patients
Living With Systolic Hypertension (ACCOMPLISH)
trial investigated antihypertensive combination treat-
ment with benazepril+amlodipine (B+A) or benazep-
ril+hydrochlorothiazide (B+H) on CV outcomes in
patients with systolic hypertension and with widely
varying PPs.3,4 The overall study result was significantly
lower for CV outcomes in the patients randomized to
B+A compared with B+H despite no differences in the
achieved BP between groups.
PP is an indicator of arterial stiffness and is related to
an increased risk for CV disease.5–11 Results from the
Framingham Heart Study show that for a given SBP,
coronary heart disease rates increase with lower dia-
stolic BP (DBP) values (ie, increasing PP). Although this
has been known for a long time, very little is addressed
in guidelines and treatment recommendations about
how to handle PP information in risk assessment. PP
may be better for risk prediction than SBP in high-risk
populations such as the elderly. Different treatments for
hypertension may affect PPs differently, which might
have therapeutic implications. Despite this, very few
studies have investigated the effect of different antihy-
pertensive treatments in relation to PP12 and current
guidelines lack recommendations on this subject.13,14
The aim of this retrospective analysis of the ACCOM-
PLISH trial was to investigate whether the superiority of
the combination treatment B+A over B+H on a com-
bined primary endpoint derived from the ACCOM-
PLISH trial was dependent on baseline PP. Secondary
aims were to study whether the superiority of the
combination treatment B+A over B+H on total stroke
and total myocardial infarction (MI) was separately
dependent on baseline PP.
MATERIAL AND METHODS
The complete design of the ACCOMPLISH study has
been published previously.4 In brief, the ACCOMPLISH
Address for correspondence: Per Skoglund, MD, Karolinska University
Hospital, F4:03, 17176 Stockholm, Sweden
E-mail: per.skoglund@karolinska.se
Manuscript received: August 21, 2014; revised: October 21, 2014;
accepted: October 25, 2014
DOI: 10.1111/jch.12460
The Journal of Clinical Hypertension Vol 17 | No 2 | February 2015 141
ORIGINAL PAPER
trial was a randomized, double-blinded, multicenter
trial (a total of 548 centers in the United States, Sweden,
Norway, Denmark, and Finland) that compared the
effect of B+A and B+H in preventing a composite of
fatal and nonfatal CV outcomes. Participants included
in the trial were 55 years and older with either SBP ≥160
mm Hg or currently receiving antihypertensive therapy.
Included patients had evidence of CV and or renal
disease or other target organ damage or diabetes.
Endpoints
The primary endpoint in the current subanalysis of the
ACCOMPLISH trial was a combined endpoint of CV
morbidity and/or mortality. CV morbidity was defined
as nonfatal acute MI or nonfatal stroke. CV mortality
was defined as death caused by sudden cardiac death,
fatal MI, fatal stroke, death caused by coronary
intervention, or death caused by congestive heart failure
or other CV causes. This is the same as the overall
primary endpoint in ACCOMPLISH (time to first event
for CV death or CV event) except for the removal of the
following (in CV events): hospitalization for unstable
angina, coronary revascularization, or resuscitation
after sudden cardiac arrest.
Secondary endpoints in the current subanalysis con-
sisted of MI (nonfatal and fatal) and stroke (nonfatal
and fatal). An endpoint committee adjudicated all
endpoints according to standard criteria. The members
of the endpoint committee were unaware of the study
group assignments and were not active investigators or
staff of the sponsor, Novartis Pharmaceuticals.
BP Measurement
BP was measured according to the 1988 American
Heart Association committee report on BP determina-
tion15 using a calibrated standard sphygmomanometer
or a calibrated digital device and an appropriately sized
cuff. BP was measured three times at each study visit at
1- to 2-minute intervals after the patient had remained
in a seated position for 5 minutes and was recorded as
the average of the three measurements.
There was no formal washout period for patients with
ongoing antihypertensive treatment. Patients already
taking treatment for hypertension were to discontinue
ongoing treatment after visit 1, resulting in a 2-week
period of no antihypertensive treatment until switching
to the blinded study drugs after randomization.
Statistical Analysis
In our current subanalysis, patients were divided into PP
tertiles (high, medium, and low) based on their baseline
PP. Normally distributed data were presented as
meanstandard deviation in the three tertiles. First,
hazard ratios (HRs) with 95% confidence intervals (CIs)
for the primary and secondary endpoints for each of the
tertiles (high vs low, high vs medium, and medium vs
low) were calculated pooling the two treatment groups
using a Cox regression model that included age,
coronary artery disease (yes/no), and diabetes mellitus
(yes/no) as covariates. Second, HRs with 95% CIs for
the primary and secondary endpoints for treatment
effect (B+A over B+H) were calculated in all PP tertiles
using the same Cox regression model. Finally, HRs for
treatment effects were compared among all PP tertiles.
SAS version 9.3 (SAS Institute Inc, Cary, NC) was used
for statistical analysis. A P value <.05 was considered
significant.
RESULTS
The ACCOMPLISH trial was terminated early when
the limit of the prespecified stopping criterion was
reached after a mean study duration of 35.7 months.
There was a highly significant treatment effect in favor
of the B+A combination, which has been described
elsewhere.3 Of the 13,782 screened patients, 11,499
underwent randomization (5741 to B+A and 5758 to
B+H) in ACCOMPLISH and were included in this
subanalysis. Baseline characteristics between randomly
assigned study patients in the two treatment arms were
similar and are presented in Table I in relation to
tertiles of PP. The mean age of patients in the
ACCOMPLISH trial was 68.4 years, and 39.5% were
women. Laboratory data of the study patients are
presented in Table II.
The mean PP in the whole study group was 65.2
mm Hg. The mean PPs in the different tertiles of PP
were 50.3 mm Hg, 63.9 mm Hg, and 82.2 mm Hg,
respectively. Of randomized patients, most (97.2%)
were taking antihypertensive treatment before the trial,
although only 37.3% had a normal BP level at baseline.
After 6 months in the trial, when titration of antihy-
pertensive treatment was complete, mean doses in the
B+A group were 36.3 mg benazepril and 7.7 mg
amlodipine and 1662 (29%) patients received addi-
tional agents. In the B+H group, mean doses were 36.1
mg of benazepril and 19.3 mg of hydrochlorothiazide
and 1636 (29%) patients received additional antihyper-
tensive agents. At the end of the trial, outcome data
were unavailable in 143 participants: 5 withdrew their
consent, 21 were from sites affected by natural disaster
that forced them to end their activity, and 117 (1.0%)
were lost to follow-up. The results are based on an
intention-to-treat design.
Comparisons between tertiles of PP, pooling the two
treatment groups, showed an increased incidence of the
primary endpoint (CV mortality/nonfatal MI/nonfatal
stroke) in the high tertile compared with the low tertile
and in the high tertile compared with the medium tertile
of PP (P<.01) (Table III). For the secondary endpoint
(all MI), a similar association was observed. No
significant association was observed between PP and
the incidence of stroke.
Secondly, HRs for B+A over B+H were calculated in
the three tertiles of PP in a Cox regression model
adjusted for age, diabetes mellitus, and previous MI.
The HRs for the primary endpoint for B+A over B+H
were significant in the high and medium tertiles of PP
(Table IV). There were, however, no significant
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differences between tertiles of PP when comparing HRs:
high PP vs low PP (P=.34), medium PP vs low PP
(P=.33), high PP vs medium PP (P=.93), and overall
among tertiles (P=.56) (Table IV).
The difference in event rates of the secondary
endpoints MI and stroke between the two treatment
groups across the PP tertiles is shown in the Figure. The
HRs favored B+A in both endpoints and tertiles except
for all MI in the low PP tertile. However, none of these
HRs were significant. Differences in HRs between
tertiles were not significant: high PP vs low PP
(P=.27), medium PP vs low PP (P=.18), high PP vs
medium PP (P=.70), and overall among tertiles (P=.39)
for all MI and high PP vs low PP (P=.54), medium PP vs
low PP (P=.99), high PP vs medium PP (P=.53), and
overall among tertiles (P=.76) for all stroke.
TABLE I. Baseline Characteristics of the Study Patients According to Tertiles of Pulse Pressure and Treatment
Low Tertile
(Mean PP=50.3 mm Hg)
(<58 mm Hg)
Medium Tertile
(Mean PP=63.9 mm Hg)
(58–70.7 mm Hg)
High Tertile
(Mean PP=82.2 mm Hg)
(≥70.7 mm Hg)
B+A (n=1888) B+H (n=1881) B+A (n=1924) B+H (n=1887) B+A (n=1929) B+H (n=1990)
Sex (male/female) 1213/675 1247/634 1175/749 1157/730 1059/870 1109/881
Mean age (y) 66.9 (6.49) 66.4 (6.36) 68.4 (6.70) 68.4 (6.74) 70.0 (7.02) 70.0 (6.97)
BMI (kg/m2) 31.34 (6.09) 31.56 (6.31) 31.13 (6.30) 30.89 (6.20) 30.39 (6.24) 30.36 (6.11)
Antihypertensive treatment at start (yes) 1886 1874 1896 1857 1834 1914
SBP (mm Hg) 129.7 (11.9) 129.7 (11.4) 144.0 (11.2) 144.1 (11.2) 161.9 (15.1) 161.4 (14.7)
DBP (mm Hg) 80.3 (10.2) 80.6 (9.8) 80.1 (10.6) 80.3 (10.6) 79.9 (11.6) 79.0 (14.7)
Heart rate (bpm) 71.4 (10.8) 71.4 (10.7) 71.0 (10.9) 70.5 (10.9) 69.0 (10.8) 69.1 (11.5)
History of CV disease
MI (yes) 452 (23.9) 487 (25.9) 459 (23.9) 450 (23.8) 426 (22.1) 435 (21.9)
Unstable angina (yes) 241 (12.8) 235 (12.5) 201 (10.4) 221 (11.7) 210 (10.9) 215 (10.8)
CABG (yes) 394 (20.9) 374 (19.9) 441 (22.9) 393 (20.8) 412 (21.4) 430 (21.6)
PCI (yes) 424 (22.5) 436 (23.2) 333 (17.3) 340 (18.0) 296 (15.3) 346 (17.4)
History of stroke (yes) 254 (13.5) 257 (13.7) 249 (12.9) 243 (12.9) 258 (13.6) 236 (11.9)
Diabetes mellitus (yes) 1099 (58.2) 1083 (57.6) 1198 (62.3) 1121 (59.4) 1180 (61.2) 1262 (63.4)
Other risk factors
Current smoking (yes) 216 (11.4) 230 (12.2) 228 (11.9) 226 (12.0) 197 (10.2) 202 (10.2)
Atrial fibrillation (yes) 137 (7.3) 128 (6.8) 110 (5.7) 135 (7.2) 129 (6.7) 139 (7.0)
LVH by ECG (yes) 180 (9.5) 152 (8.1) 228 (11.9) 231 (12.2) 354 (18.4) 374 (18.8)
Abbreviations: B+A, benazepril+amlodipine; B+H, benazepril+hydrochlorothiazide; BMI, body mass index; CABG, coronary angioplastic bypass surgery;
CV, cardiovascular; DBP, diastolic blood pressure; ECG, electrocardiogram; LVH, left ventricular hypertrophy; MI, myocardial infarction; PCI,
percutaneous coronary intervention; SBP, systolic blood pressure; Unstable angina, hospitalization for unstable angina. Data are number of patients,
(%) or mean (SD) were appropriate if nothing else is stated. Missing data in each subgroup varied from 0 to 4.
TABLE II. Laboratory Data in Relation to Tertiles of PP and Treatment
Low Tertile
(Mean PP=50.3 mm Hg)
(<58 mm Hg)
Medium Tertile
(Mean PP=63.9 mm Hg)
(58–70.7 mm Hg)
High Tertile
(Mean PP=82.2 mm Hg)
(≥70.7 mm Hg)
B+A (n=1888) B+H (n=1881) B+A (n=1924) B+H (n=1887) B+A (n=1929) B+H (n=1990)
Serum glucose, mg/dL 125.3 (48.2) 123.9 (44.0) 128.2 (45.0) 126.7 (44.4) 130.0 (48.8) 130.1 (48.6)
Total cholesterol, mg/dL 182.9 (41.2) 180.3 (37.4) 184.4 (39.7) 183.9 (39.2) 187.5 (40.5) 187.9 (40.8)
HDL cholesterol, mg/dL 48.9 (14.0) 48.1 (13.3) 49.5 (13.8) 49.4 (14.2) 50.4 (14.5) 51.0 (14.6)
hsCRP, mg/L 0.459 (1.0) 0.447 (0.7) 0.466 (1.0) 0.452 (0.8) 0.450 (0.9) 0.457 (0.8)
eGFR, mL/min/1.73 m2 79.5 (20.8) 81.1 (21.6) 79.7 (21.5) 79.1 (21.3) 77.5 (21.1) 77.2 (21.5)
GFR (MDRD), %
<60 314 (16.6) 292 (15.5) 350 (18.2) 338 (17.9) 381 (19.8) 398 (20.0)
60–90 1046 (55.4) 1009 (53.6) 1031 (53.6) 1042 (55.2) 1074 (55.7) 1136 (57.1)
>90 524 (27.8) 576 (30.6) 538 (28.0) 503 (26.7) 471 (24.4) 453 (22.8)
Abbreviations: B+A, benazepril+amlodipine; B+H, benazepril+hydrochlorothiazide; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive
protein; GFR (MDRD), estimated glomerular filtration rate calculated according to Modification of Diet in Renal Disease; PP, pulse pressure. Data are
expressed as number of patients (percentage) or mean (standard deviation) unless otherwise indicated. Missing data in each subgroup varied from 0
to 4.
The Journal of Clinical Hypertension Vol 17 | No 2 | February 2015 143
Pulse Pressure in ACCOMPLISH | Skoglund et al.
DISCUSSION
In this subanalysis of the ACCOMPLISH trial, PP was a
strong predictor of future CV events, thus confirming
findings from previous studies.6–11 The novel finding of
this study was that the superiority of B+A treatment
compared with B+H was independent of the baseline
office PP.
When analyzing the different tertiles, the difference in
PP between the tertiles is a consequence of an increase in
SBP. This implies that our findings are caused by
differences in SBP rather than PP per se. However, in
hypertensive patients with healthy vascular morphol-
ogy, a rise in SBP would be accompanied by a rise in
DBP as well, resulting in almost the same PP between
patients independently of SBP values. In our study
population, elevated SBPs are obviously not appropri-
ately accompanied by elevated DBPs, resulting in higher
PPs. This is most likely the result of a more advanced
vascular disease with arterial stiffness in the groups with
higher PP.5–11
When comparing CV events in the pooled treatment
groups, high and medium baseline PP was associated
with CV morbidity and/or mortality and total MI. We
also found a trend toward more strokes in the highest PP
tertile, although not significant. This is consistent with
another subanalysis of ACCOMPLISH that showed
better CV outcomes in patients with achieved SBP <140
mm Hg and <130 mm Hg compared with SBP >140
mm Hg.16 A high PP may be a stronger predictor for MI
than stroke. Two possible explanations for this effect on
MI may be that an elevated SBP may promote cardiac
hypertrophy while a decrease in DBP can cause a
decrease in coronary perfusion.12 Stroke, on the other
hand, appears to be primarily related to SBP levels.16
Similar findings to those found in our study have been
seen in healthy patients,8 patients with high PP,6 and in
untreated hypertensive men.9 Our findings are also
TABLE III. Number of Events According to Tertiles of Pulse Pressure and Between-Tertile Hazard Ratios
High vs Low Medium vs Low High vs Medium
CV mortality/nonfatal MI/nonfatal stroke 284 (7.2) vs 164 (4.4)
1.48 (1.22–1.80)a
204 (5.4) vs 164 (4.4)
1.16 (0.94–1.42)
284 (7.2) vs 204 (5.4)
1.28 (1.07–1.54)a
All MI 136 (3.5) vs 64 (1.7)
2.01 (1.48–2.73)a
84 (2.2) vs 64 (1.7)
1.29 (0.93–1.79)
136 (3.5) vs 84 (2.2)
1.56 (1.19–2.05)a
All stroke 104 (2.7) vs 66 (1.8)
1.22 (0.89–1.78)
75 (2.0) vs 66 (1.8)
1.00 (0.72–1.40)
104 (2.7) vs 75 (2.0)
1.22 (0.91–1.65)
Abbreviations: CV, cardiovascular; MI, myocardial infarction. Data are expressed as number of patients with events (percentage) and hazard ratio (95%
confidence interval). aP<.01.
TABLE IV. Between-Treatment HRs Across PP Tertiles for the Primary Endpoint Cardiovascular Mortality/Nonfatal
Myocardial Infarction/Nonfatal Stroke
Baseline PP Tertiles CV Events/No. (B+A) CV Events/No. (B+H) HR 95% CI P Value
High 120/1929 (6.2) 164/1990 (8.2) 0.75 0.60–0.95 .018
Medium 89/1929 (4.6) 115/1887 (6.1) 0.74 0.56–0.98 .034
Low 79/1888 (4.2) 85/1881 (4.5) 0.91 0.67–1.23 .54
Abbreviations: B+A, benazepril+amlodipine; B+H, benazepril+hydrochlorothiazide; CI, confidence interval; CV, cardiovascular; PP, pulse pressure.
Comparing treatment hazard ratios (HRs) between tertiles (high vs low P=.34, medium vs low P=.33, high vs medium P=.93, overall among tertiles P=.56).
Values are expressed as numbers (percentages) in each tertile and treatment group, respectively.
FIGURE. Between-treatment hazard ratios across pulse pressure
(PP) tertiles by baseline PP for the indicated endpoint. AMLO,
amlodipine; BZPL, benazepril; HCTZ, hydrochlorothiazide; MI,
myocardial infarction; PP, pulse pressure; CAD, coronary artery
disease. Bars express the 95% confidence interval. Hazard ratio for
BZPL/AMLO over BZPL/HCTZ is based on a Cox regression model
with treatment, baseline PP tertile, and treatment-by-PP tertile
interaction as factors and baseline age, CAD (yes/no), and Diabetes
Mellitus (yes/no) as covariates. Hazard ratios comparing treatments
between tertiles were not significant at P<.05 (High vs Low, Medium
vs Low, High vs Medium, and overall among tertiles P=.39 for all MI
and P=.76 for all stroke) by baseline PP.
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compatible with the recently reported finding that the
effect of high BP varies by CV disease endpoint.2
In our subanalysis of ACCOMPLISH, there was no
significant difference between PP tertiles for the treat-
ment effect. To our knowledge, the association between
PP and treatment effect has been reported from only one
large hypertension study. The Losartan Intervention for
Endpoint Reduction in Hypertension (LIFE) study
demonstrated the superiority of treatment with losartan
(an angiotensin II receptor antagonist) over atenolol (a
b-blocker) in reducing CV events in high-risk hyperten-
sive patients.17 In a post hoc analysis of that study, a
higher PP was significantly related to an increased
number of CV events in the atenolol-treated group,
whereas the same pattern, although not significant, was
observed in the group treated with losartan.17,18
Although the relationship of the reported numbers of
events in categories of PP and treatment show similar
patterns compared with our study, the differences in
baseline characteristics and statistical methodology
hamper the comparison to our study.
In absolute numbers, a larger treatment effect was
observed in the two higher tertiles compared with the
lowest tertile. The lack of significant differences
between PP tertiles for the relative treatment effect in
the current study could be the result of a type 2 error.
Further, a categorization of PP based on standard BP
measurements may be inferior in comparison to
24-hour19 and central pressure measurements.20,21 In
the ACCOMPLISH trial, the difference in SBP between
the two treatment groups was <1 mm Hg. This indicates
that there are other mechanisms than the reduction of
brachial BP that are responsible for the superiority of
B+A over B+H in preventing CV disease events. Another
trial that studied the effect of a calcium channel blocker
(CCB) in patients with high PP is the Systolic Hyper-
tension in Europe (Syst-Eur) trial.22 In Syst-Eur, the
24-hour average PP, before the initiation of drug
therapy, was the most important factor predicting CV
disease risk.23 It was shown that the reduction of CV
events correlated with the PP reduction on CCB
treatment. Twenty-four–hour BP monitoring is a more
precise method for determining a patient’s true BP over
time and is therefore a better marker for CV risk and
outcomes.24 It has also been suggested that office BP
underestimates 24-hour BP in patients with established
CV disease.25 Ambulatory BP measurement was per-
formed in only a subset of the ACCOMPLISH patients.
Achieved BP after 2 years did not differ between the two
treatment arms.26 However, the reduction in 24-hour
BP from baseline BP in relation to the two treatment
arms in ACCOMPLISH have not been reported. Taking
this into account, BP values at baseline in our current
study (especially in patients with more advanced CV
disease) may not be the best predictors of events and so
might have affected the findings in our present study.
Since high PP is a risk factor for CV disease,
identification of a treatment tailored to patients with
high PP would have high clinical relevance. High PP is
common among the elderly22 and clearly identifies
patients at high risk. Further, PP is a powerful predictor
for CV events27 and seems to play a particularly
important prognostic role in older, hypertensive, and
diseased populations than in healthy, middle-aged
populations.28–31 Studies are needed to investigate
whether the effects of treatments to prevent CV events
are dependent on PP levels and also to investigate
whether patients with stiff arteries benefit more from
CCB-based treatment (measuring central pressure),
especially since PP is the most important predictor of
CV disease risk in elderly patients.32 However, no
studies have evaluated PP as a treatment goal and
should now be considered. Such studies could be
performed using available data from previous large
outcomes trials.
CONCLUSIONS
This subanalysis of the ACCOMPLISH trial shows that
high PP is related to higher incidence of CV death,
nonfatal MI, and stroke in a group of high-risk
hypertensive patients. The superiority of the combina-
tion treatment B+A over B+H in hypertensive patients
existed irrespective of baseline PP, but the absolute
treatment effect may be enhanced in the higher tertiles
of PP.
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